Nkarta, Inc.
Nkarta, Inc. (NKTX) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · NKTX · as of Jun 9, 2026
Key Statistics
Explore Nkarta, Inc. Data
nktx stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 12 · Buy rate: 83.3%
The NKTX analyst consensus is Buy, based on ratings from 12 Wall Street analysts over the past 3 months. The average 12-month price target is $9.00, representing +275.00% upside from the current price of $2.40.
Competitors & Peers
nktx competitorsNKTX
ALEC
APLT
CYBN
ELTX
FATEStock Performance
Full HistoryAbout Nkarta, Inc.
Nkarta, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to advancing and marketing cell-based treatments for cancer. Their innovative cellular immunotherapy strategy outfit…
what is nkarta, inc. · nktx stock overview · nkarta, inc. company profile · who is nkarta, inc. ceo · nktx NASDAQ · nkarta, inc. headquarters · nkarta, inc. business segments
About Stock Overview & Key Data
Nkarta, Inc. (NKTX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jul 10, 2020. As of the latest trading session, NKTX stock price is $2.40, with a market capitalization of $171.7M. The stock has returned +28.34% over the past 12 months and +29.73% year-to-date.
According to 12 Wall Street analysts, the consensus rating for Nkarta, Inc. stock is Buy, with an average 12-month price target of $9.00. In fiscal year 2025, Nkarta, Inc. reported revenue of — and net income of -$104.1M. For detailed data — including Nkarta, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Nkarta, Inc. (NKTX) stock price is $2.40. The stock is traded on NASDAQ under the ticker symbol NKTX. The 52-week range is $1.63 – $3.65.